Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bill and Melinda Gates Foundation

- PMLiVE

Gilead bags EU approval for next-generation HIV drug

Descovy expected to replace Truvada as the firm’s lead antiviral blockbuster

- PMLiVE

Gilead boosts liver disease pipeline with $1.2bn acquisition

Also has combination HIV therapy Descovy approved by FDA

Gilead Sciences

Gilead wins US approval for second TAF-based HIV drug

FDA gives Odefsey the green light

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

- PMLiVE

Novartis to make 15 drugs available at $1 a month

Comes after concerns surrounding hiked drug prices and effects on public health

- PMLiVE

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 

- PMLiVE

Bionor gears up for ‘kick and kill’ HIV data

Could also be used in conjunction with Celgene's cancer drug Revlimid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links